Y-Biologics

Y-Biologics develops antibody-based medicines, laboratory-engineered proteins designed to target and block disease-causing molecules in the body, with a focus on cancer immunotherapy and other areas of unmet medical need.

It operates on two business models: licensing its drug candidates and platform technology to larger pharmaceutical companies, and providing contract research services to generate ongoing revenue. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company runs a pipeline of independently developed candidates alongside programs co-developed with partners, spanning formats such as bispecific antibodies and antibody-drug conjugates.